EMA To Publish All COVID-19 Clinical Data
Move Welcomed By Transparency Advocates
The European Medicines Agency says the unprecedented public interest in treatments and vaccines being developed for COVID-19 has highlighted the need to provide access to more information than usual.
You may also be interested in...
European Medicines Agency chief Guido Rasi has responded to questions by the European Ombudsman about its COVID-19 Pandemic Task Force.
The European Medicines Agency has started reviewing under its fast-track pathway an application to market Dexamethasone Taw as a treatment for hospitalized patients with COVID-19.
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.